<div id="readability-page-1"><p><span>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report)</span>'s stock had its &#34;equal weight&#34; rating reaffirmed by equities researchers at Wells Fargo &amp; Company in a note issued to investors on Monday,Benzinga reports. They presently have a $42.00 price target on the stock, up from their prior price target of $35.00. Wells Fargo &amp; Company's price objective would indicate a potential upside of 6.03% from the company's previous close.</p><ul><li>Wake Up to This Biotech Stock That Still Has Big Potential Upside</li></ul><p>Several other research firms have also recently weighed in on CNTA. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Guggenheim cut shares of Centessa Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, April 2nd. Wolfe Research cut shares of Centessa Pharmaceuticals from an &#34;outperform&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, March 31st. Stephens cut shares of Centessa Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, March 31st. Finally, Leerink Partners cut shares of Centessa Pharmaceuticals from an &#34;outperform&#34; rating to a &#34;hold&#34; rating and upped their price objective for the stock from $36.00 to $40.00 in a research report on Wednesday, April 1st. Four investment analysts have rated the stock with a Buy rating, nine have assigned  a Hold rating and one  has assigned  a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of &#34;Hold&#34; and a consensus target price of $40.70.</p><p><b>Read Our Latest Report on Centessa Pharmaceuticals</b></p><h2>Centessa Pharmaceuticals Stock Performance</h2><p>Centessa Pharmaceuticals stock traded down $0.05 during midday trading on Monday, reaching $39.61. The stock had a trading volume of 819,934 shares, compared to its average volume of 2,431,604. Centessa Pharmaceuticals has a 12 month low of $10.95 and a 12 month high of $40.26. The firm's 50-day moving average price is $30.15 and its 200 day moving average price is $26.76. The firm has a market capitalization of $6.12 billion, a PE ratio of -26.95 and a beta of 1.25. The company has a quick ratio of 8.57, a current ratio of 8.57 and a debt-to-equity ratio of 0.21. </p><p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.10).  As a group, research analysts predict that  Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year. </p><h2>Insider Buying and Selling at Centessa Pharmaceuticals</h2><p>In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of the firm's stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the transaction, the insider owned 65,925 shares of the company's stock, valued at approximately $1,735,805.25. This trade represents a 52.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Iqbal J. Hussain sold 38,951 shares of the firm's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total value of $979,617.65. Following the transaction, the insider owned 57,645 shares of the company's stock, valued at $1,449,771.75. The trade was a 40.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 349,073 shares of company stock valued at $9,429,412. 7.09% of the stock is currently owned by company insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors and hedge funds have recently bought and sold shares of the company. TD Waterhouse Canada Inc. bought a new stake in  Centessa Pharmaceuticals during the 4th quarter worth approximately $25,000.  Caitong International Asset Management Co. Ltd purchased a new stake in shares of  Centessa Pharmaceuticals during the 4th quarter worth approximately $36,000.  T. Rowe Price Investment Management Inc. raised its holdings in shares of  Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company's stock worth $39,000 after acquiring an additional 1,516 shares in the last quarter.  Wells Fargo &amp; Company MN raised its holdings in shares of  Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo &amp; Company MN now owns 3,387 shares of the company's stock worth $85,000 after acquiring an additional 1,008 shares in the last quarter.  Finally, Knott David M Jr purchased a new position in  Centessa Pharmaceuticals during the fourth quarter worth $100,000. 82.01% of the stock is owned by hedge funds and other institutional investors. </p><h2>Centessa Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&amp;D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain. </p><p>Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Centessa Pharmaceuticals</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Centessa Pharmaceuticals Right Now?</h2><p>Before you consider Centessa Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.</p><p>While Centessa Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CNTA

<p>Wells Fargo & Company has reaffirmed an "equal weight" rating for Centessa Pharmaceuticals (NASDAQ:CNTA) and raised its target price from $35.00 to $42.00, indicating a potential upside of 6.03%. The stock is currently rated as "Hold" by analysts, with an average target price of $40.70. Recent trading saw the stock at $39.61, with a 12-month range of $10.95 to $40.26. Insider trading activity has seen significant sales, with 7.09% of shares held by insiders. Institutional investors have also been active in buying and selling shares recently.</p>

Market Beat

Centessa Pharmaceuticals

Wells Fargo

Toronto Dominion Bank

T. Rowe Price

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Centessa Pharmaceuticals' (CNTA) Equal Weight Rating Reaffirmed at Wells Fargo & Company